Metastasis-associated protein 1 (MTA1), a master chromatin modifier, has been shown to regulate cancer progression and is widely upregulated in human cancer, including hepatitis B virus-associated hepatocellular carcinomas (HCCs). Here we provide evidence that hepatitis B virus transactivator protein HBx stimulates the expression of MTA1 but not of MTA2 or MTA3. The underlying mechanism of HBx stimulation of MTA1 involves HBx targeting of transcription factor nuclear factor (NF)-jB and the recruitment of HBx/p65 complex to the NF-jB consensus motif on the relaxed MTA1 gene chromatin. We also discovered that MTA1 depletion in HBx-expressing cells severely impairs the ability of HBx to stimulate NF-jB signaling and the expression of target proinflammatory molecules. Furthermore, the presence of HBx in HBx-infected HCCs correlated well with increased MTA1 and NF-jB-p65. Collectively, these findings revealed a previously unrecognized integral role of MTA1 in HBx stimulation of NF-jB signaling and consequently, the expression of NF-jB targets gene products with functions in inflammation and tumorigenesis.
Introduction
Hepatocellular carcinoma (HCC) is the most common form of liver cancer in adult that accounted for 1 million deaths every year worldwide (Dvorchik et al., 2007) . Of those, high morbidity and mortality rate are found in Asia and Africa. In the United States, according to the American Cancer Society, there will be 22 000 new cases of HCC, up to 19 000 of them fatal, during the year of 2008. Over the years, a large number of epidemiological studies suggest that more than 75% of HCC cases are associated with chronic hepatitis B virus (HBV) and/or hepatitis C virus (HVC). The infection of HBV increases the risk of a wide spectrum of clinical manifestations ranging from self-limited acute or fulminant hepatitis, asymptomatic infection or chronic hepatitis with progression to liver cirrhosis that can lead to HCC. Indeed, elevated serum HBV DNA level is a strong risk predictor of HCC (Chen et al., 2006; Lupberger and Hildt, 2007) . The circular virion genome of HBV has four overlapping reading frames that are responsible for the generation of seven different hepatitis B proteins. Being encoded by the X gene, the smallest reading frame, HBx has been implicated in the regulation and transactivation of a variety of cellular genes in hepatocytes. HBx targets a gamut of cytoplasmic and nucleus gene products with diverse functions including modulating nuclear factor (NF)-kB signaling, regulating cell survival and producing inflammatory cytokines, contributing to HBV infection, replication, pathogenesis and putatively to carcinogenesis (Bouchard and Schneider, 2004) .
Among the Rel/NF-kB family of proteins, the RelA (p65) and NF-kB1 (p50; p105) have crucial roles in immune response, cell survival and cellular transformation (Pahl, 1999; Li and Verma, 2002) . A notable body of literature suggests that HBx interacts with all major forms of NF-kB and activates target promoters bearing NF-kB, cAMP-response element and AP-1 consensus motifs (Chirillo et al., 1996; Bergametti et al., 1999; Hoffmann and Baltimore, 2006) ; induces the degradation of p105 NF-kB1 and IkBa (Su and Schneider, 1996; Zhang et al., 2006) or sequesters IkBa to sustain NF-kB activation (Lucito and Schneider, 1992; Weil et al., 1999; Yun et al., 2002) , where its activity is enhanced by VHL binding protein in a cooperative manner ). Yet, the mechanism for HBx activation of NF-kB remains undefined.
In addition to HBV, the process of liver carcinogenesis has been also shown to be intimately linked with the upregulation of metastasis-associated protein 1 (MTA1), a component of nucleosome remodeling histone deacetylase (NURD) complex (Yoo et al., 2008) . The MTA family has emerged not only as a crucial modifier of chromatin remodeling but also as a potential prognostic indicator after hepatectomy for HCC (Hamatsu et al., 2003; Manavathi and Kumar, 2007) . MTA1 overexpression has been shown to associate with carcinogenesis and angiogenesis in animal tumor model systems and in human cohort studies (Manavathi et al., 2007b) in addition to be consistently correlated with a higher tumor grade and increased tumor angiogenesis in gastrointestinal carcinoma tumors (Kidd et al., 2006) and in colorectal carcinoma as compared to the matched normal tissues (Giannini and Cavallini, 2005) . In postoperative patients with HCC, MTA1 expression in HBV associated HCC is higher than that of HCV-associated HCC, although the median survival rate of the MTA1-positive patients with HCC has been shown to significantly shorter than those with MTA1-negative HCCs (Ryu et al., 2008) . Although these studies suggest a strong positive correlation between the HBx and MTA1 in HCC (Yoo et al., 2008) , the role of MTA1 in HBx regulation of cellular pathways remains poorly understood. Here we elucidated the molecular basis of MTA1 upregulation in HBx-transfected cells and unexpectedly discovered a mandatory role of MTA1 in HBx regulation of NF-kB signaling and consequently, the expression of NF-kB target genes that collectively have a vital role in HBV-mediated hepatocarcinogenesis.
Results

HBx induces MTA1 expression at the transcription level
To investigate the potential mechanistic basis between the HBx and MTA1, we first tested the effect of increasing amount of HBx on the levels of MTA1 expression in a human hepatocarcinoma cell line HepG2. We found that HBx expression in HepG2 is accompanied by increased expression of MTA1 ( Figure 1a ) but not of MTA2 or MTA3 (Figure 1b) . Similarly, we also noticed a substantial upregulation of MTA1 in HepG2X, an HBx-stable transfectant of HepG2 as compared with vector-transfected cells (Ding et al., 2005) or in nonhepatic cell line human embryonic kidney (HEK) 293 (Figure 1c ). Because HCC has been also linked with HCV (Ray and Ray, 2001) , we examined whether HCV core protein also influences MTA1 expression. However, we found only albeit effect of HCV overexpression on the level of MTA1 in HepG2 cells (Figure 1d ), suggesting that MTA1 is preferably induced by HBx and not by HCV core protein.
The observed upregulation of MTA1 protein by HBx was at transcriptional level as HBx-mediated induction of MTA1 mRNA could be effectively blocked by the inclusion of actinomycin D, a DNA replication inhibitor (Figure 1e ). To further validate these findings, we next tested the effect of HBx on a murine MTA1 promoter cloned in a TATA-lesspGL3-luciferase reporter system. We found that HBx expression in HepG2, HEK 293 (Figure 1f , supplementary Figure S1A and supplementary Figure S1B , respectively) and HepG2X cells (Figure 1g ) was accompanied by stimulation of the MTA1 transcription. In brief, HBx induces MTA1 expression at the transcription level.
HBx uses NF-kB pathway to stimulate MTA1 transcription The activation of NF-kB and resulting stimulation of the NF-kB transactivation activity confers cell-survival phenotype in HBx-expressing cells (Su and Schneider, 1996; Yun et al., 2002) . Recent data from our laboratory suggest that MTA1 promoter contains five NF-kB consensus sites and that p65/RelA directly binds and stimulates MTA1 transcription (SB Pakala and R Kumar, unpublished findings, paper in review elsewhere). We examined the mechanism by which HBx stimulates MTA1 transcription with a particular focus on the NF-kB pathway. To examine the use of the NF-kB pathway by HBx to induce MTA1 expression, we showed that HBx-mediated stimulation of the MTA1 promoter activity in HepG2 cells could be effectively blocked by the inclusion of NF-kB-inhibitor parthenolide ( Figure 2a ). Because HBx uses p65 pathway to stimulate MTA1 transcription (above), there was no additional potentiating effect of coexpressing HBx and p65 on the MTA1 promoter activity (Figure 2b , supplementary Figure S1C ). To define the molecular insights of HBx regulation of MTA1 chromatin, we next determined the region of the MTA1 promoter that is being targeted by HBx by performing a chromatin immunoprecipitation (ChIP)-based MTA1 promoter walk in HepG2-transiently expressing HBx. Recruitment of HBx or p65 to all four potential NF-kB consensus sites was analyzed. Flag-tagged antibodybased and p65 antibody-based ChIP analysis showed that HBx as well as p65 were recruited onto two regions of the MTA1 promoter (À3814 to À4152 and À2874 to À3207). Because HBx induces the expression of MTA1, we also examined whether acetylated histone H4, a marker of relaxed activated chromatin, is also recruited to the same sites in the MTA1 promoter in the HBx-expressing cells. Indeed, Acetylated H4 antibodybased ChIP analysis again showed that acetylated H4 is recruited to the regions of MTA1 promoter targeted by HBx (Figure 2c ). Using sequential ChIPs, we further showed that HBx/p65 complex is recruited to the MTA1 promoter and such recruitment could be substantially reduced by NF-kB-inhibitor parthenolide (Figure 2d ). In brief, these observations suggest that HBx/p65 binding to the MTA1 promoter leads to transcriptional stimulation of MTA1 chromatin. Because HBx is not known to bind directly to DNA, this interaction is presumed to be indirect.
Essential role of the YFKD motif in HBx regulation of MTA1 transcription To define the minimal region of HBx required for stimulation of MTA1 transcription, we used a series of well-characterized truncated mutant of HBx. We found that deletions of the N-terminal regions (aa1-84) or the nonconserved region (aa141-154) had marginal effect on the HBx-mediated MTA1 transactivation, whereas deletions in the region between residue 58 and residue 140 of HBx resulted in significant decrease in the level of HBx-mediated stimulation of MTA1 transcription. Interestingly, there was a good correlation between the effects of HBx-deletion constructs on the MTA1 promoter activity and MTA1 protein expression in HepG2 cells (Figure 3a) , providing clue about the biological significance of the region of HBx encompassing aa58-120. Because this region contains the binding motif for p65 (Vijay Kumar, personal communication) and because HBx stimulates MTA1 transcription through NF-kB pathway (this study), we wanted to define the minimal region on HBx that may impact MTA1 expression. We mutated the YFKD motif to FAEN in the full-length HBx protein (designated as mut-HBx) and examined the impact of mut-HBx on MTA1 promoter activity as well as on MTA1 upregulation. We found that as compared to the wild-type (WT) HBx, mut-HBx is unable to efficiently induce the MTA1 promoter activity as well as MTA1 protein in HepG2, NIH3T3 and murine embryonic fibroblasts (MEFs; Figure 3b , supplementary Figure S2A -B).
Although a large body of previous HBx studies have suggested both direct and indirect involvement of NF-kB to HBx transactivation, evidence showing direct interaction between HBx and NF-kB-p65 remains elusive. Hence, we next expressed the WT HBx and mut-HBx constructs as 35 S-labeled proteins and performed a glutathione S-transferase pull-down assay using the glutathione S-transferase-NF-kB-p65 fusion protein. Results in Figure 3c showed a direct interaction of the NF-kB-p65 with HBx but not with mut-HBx. These findings also confirmed that the YFKD motif has an essential role in the noted HBx-NF-kB-p65 interaction. To further validate these results and to establish the significance of the YFKD motif, we next examined the recruitment of the Flag-HBx/p65 complex to the native MTA1 chromatin by sequential ChIPs involving antibodies against the Flag and p65 in the first and second ChIPs, respectively. We found that the WT FlagHBx but not Flag-mut-HBx was recruited onto the putative binding regions of the MTA1 promoter (À3814 to À4152 and À2874 to À3207; Figure 3d ). To establish a direct interaction of the HBx protein to the NF-kB consensus motif in the MTA1 promoter DNA and the significance of the YFKD motif, we next performed electrophoretic gel mobility shift assay (EMSA). To this end, we subjected the nuclear extracts from the HepG2 cells transfected with HBx or mut-HBx to EMSA analysis using a 300-bp DNA fragment containing a single NF-kB consensus motif in the MTA1 promoter. We found that extracts from the HBx, but not from mut-HBx, expressing cells resulted in the formation of a distinct protein/DNA complex (Figure 3e , compare lane 5 with lane 2), which could be competed by the cold DNA probe (lane 8). Interestingly, the observed HBx protein/DNA complex could be effectively supershifted by anti-p65 antibodies but not by IgG (compare lane 6 with lane 8). These results suggested that HBx presumably uses NF-kB-p65 to interact with the MTA1 DNA as mut-HBx, which cannot interact with p65, was also unable to bind to MTA1 DNA fragment in the EMSA (lanes 9-14).
MTA1 is required for HBx transactivation function
Recent studies suggest that MTA1 is not only a target of p65 but also a component of NF-kB signaling network (SB Pakala, TM Bui-Nguyen and R Kumar, unpublished findings). To understand the impact of endogenous MTA1 on HBx transactivation activity, we examined the ability of HBx to induce MTA1-luc activity in the WT MEF and MEF-MTA1-KO MEFs. Unexpectedly, we found that HBx was unable to induce MTA1-luc activity in MTA1-deficient MEFs whereas it did so in the WT MEFs (Figure 4a ). To independently validate these results, we next showed that selective siRNA-mediated knockdown of MTA1 in HepG2 cells also impaired both the basal and HBx-induced MTA1 promoter activity (Figure 4b ). Taken together, these results revealed an integrated role of MTA1 in the transactivation activity of HBx.
An essential role of MTA1 in HBx stimulation of NF-kB signaling As MTA1-depletion compromises HBx transactivation activity, we next examined whether HBx activation of NF-kB requires MTA1. To examine the above hypothesis, we examined the effect of MTA1-siRNA on the ability of HBx to induced NF-kB signaling pathway in HepG2 cells. As expected from the previous studies, HBx expression was accompanied by increased levels of phosphorylated IkBa and phosphorylated p65 as well as MTA1 expression. However, comparable levels of HBx in HepG2 cells were unable to induce p65/ RelA activation in the absence of MTA1 (Figure 5a ). Consistent with these results, the levels of HBx-mediated stimulation of the NF-kB DNA-binding activity was substantially reduced in MTA1-deficient MEFs as compared to WT MEFs (data not shown). We next determined whether the noticed defect in NF-kB signaling pathway by HBx under condition of MTA1 deficiency is also accompanied by a defective NF-kB-target gene expression. To explore this notion, we examined the effect of MTA1-siRNA on the ability of HBx to induce transcription from the NF-kB-luc reporter in HepG2 and MEFs. We found that MTA1 downregulation impairs the ability of HBx to induce NF-kB-luc activity (Figures 5b-c) and to induce the formation of the protein/DNA sequence harboring NF-kB consensus motif complex (Figure 5d ). Accordingly, MTA1 depletion in HepG2 by siRNA (Figure 5e , inset) also impairs the ability of HBx to induce the expression of NF-kB target genes such as COX2 and TNF-a (Figure 5e ). Because previous studies have shown a strong positive correlation of COX2 upregulation with HBx expression and in HBV-associated chronic liver diseases (Cheng et al., 2004) , these studies suggest that HBx-dependent stimulation of NF-kB signaling and resulting inflammatory targets such as COX2 and TNF-a are at least, in part, are dependent on the presence of MTA1. Together, these findings imply that HBx-induced inflammation, which overtime could contribute to transformation, may be dependent on the cellular status of MTA1. Together, these findings suggest that MTA1 has an essential mechanistic role during HBx-mediated stimulation of NF-kB signaling and resulting expression of target genes and functions.
Levels of MTA1 and p65 in HBV-infected HCC
To evaluate the significance of noted HBx regulation of MTA1 and in turn, a mechanistic role of MTA1 in HBx-induced NF-kB pathway in human HCC, we examined the expression characteristics of HBx, MTA1 and p65 in HCC specimens and matched nontumor tissue from the same patient. Western blot analysis of 22 matched sets of specimens indicated that there were 9 HCC-HBx-positive specimens out of 44 analyzed here, whereas MTA1 and p65 were upregulated in 20 and 19 samples, respectively, and consistently upregulated in HCC as compared to the matching nontumor tissues (Figure 6a) . Overall, there were 7 out of 22 HCC samples wherein HBx presence correlated with increased MTA1 and p65. Interestingly, high levels of MTA1 expression were often ensued by high levels of NF-kBp65 expression in both tumor and non-HCC samples. To further support these observations, we performed immunohistochemical analysis of 39 additional samples in microtissue array format (Figure 6b ). HCC (25) and non-HCC (14) samples were examined for the expression of HBx, MTA1 and p65 using immunohistochemical staining. There was a significant correlation between HBx expression and the detected levels of MTA1 (P ¼ 0.0001) in a mixed population of HCC and non-HCC samples. Strong correlation between the intensity of MTA1 and p65, however, was only found in HCC samples (Po0.0001) but not in non-HCC samples (P ¼ 0.46) (Figure 6c ). Altogether, our data suggest that high expression levels of HBx are accompanied by increased expression of MTA1 and p65RelA and that MTA1 has a pivotal role in HBx transactivation in HCC.
Discussion
The expression of HBx, a multifunctional HBV viral transactivator, targets a variety of cellular proteins, including NF-kB with putative functions ranging from transcription, inflammation, survival and cancerous phenotypes. However, at the moment, cellular targets of HBx have not been exploited to develop strategies to inhibit or slowdown the process of HBV-mediated HCC carcinogenesis. Overexpression of MTA1 is known to be associated with the degree of intrahepatic invasion and metastasis in patients with HCC (Hamatsu et al., 2003; Ryu et al., 2008) . While this study was in process, Yoo et al. showed that HBx induces MTA1 but that study did not address possible mechanistic insights (Moon et al., 2004) . Here we delineated the molecular mechanism underlying the induction of MTA1 by HBx and showed the integral role of MTA1 during HBxmediated activation of NF-kB signaling and its targets. We further established that although both HBV and HCV have been linked with HCC, MTA1 is targeted by HBV-HBx protein and not by HCV core protein. We further showed that HBx selectively induces MTA1 but not MTA2 and MTA3. Ongoing cloning of a murine MTA1 promoter allowed us to provide a detailed mechanistic insight of HBx regulation of MTA1 transcription. We showed that HBx targets p65 to physically interact with the MTA1 promoter containing a functional p65 motif, and such interactions lead to a productive MTA1 transcription in HBx-expressing cells. Indeed, we showed that HBx uses the YFKD motif to interact with the p65 subunit and consequently, the HBx/ p65 complex interacts with the MTA1 promoter element through the NF-kB response elements. Nevertheless, the inability of both DC-HBx (HBx with intact aa101-120) and DE-HBx (HBx with intact aa101-120) to stimulate the p65 luc-promoter activity (supplementary Figure  S1D) suggests that individual domains of HBx may not mimic the activity conferred by the intact HBx.
The HBx regulatory protein has been established by many laboratories to activate NF-kB activities in transfected cells, and this is presumed to have a role in HCC (Su and Schneider, 1996; Kim et al., 2008) . As shown in Figure 5a , we did observe a transient induction of IkBa phosphorylation, which is a direct indicator of functional upstream signaling feeding into the IkBa-p65 linearity. For reasons not fully understood at the moment, we did not observe any downregulation of IkBa protein (Figure 5a, 4th panel) as was the case in Chirillo et al. (1996) . Several possibilities may be attributable to this discrepancy such as the use of the HeLa cells by Chirillo et al. (1996) as opposed to the relevant use of HepG2 cells in our study, possible HBx interaction with papilloma virus in the HeLa cells, leading to the observed effects reported by Chirillo et al. (1996) . Although it is clear that MTA1 is essential for HBx transactivation of NF-kB, the manner by which MTA1 could feed into HBx/NF-kB pathway remains to be an important question for future investigation. Because MTA1 now affects the stability of proteins (Li et al., 2009) , it is possible that HBx-induced MTA1 in turn, stabilizes specific component or components of proximal NF-kB signaling. If so, such changes may translate into an amplified NF-kB signaling. Furthermore, because MTA1 is a chromatin modifier, it is Figure 6 Prevalence of HBx, metastasis-associated protein 1 (MTA1) and nuclear factor (NF)-kB-p65 in hepatocellular carcinoma (HCC). (a) Western blot analysis for MTA1, NF-kB-p65 and HBx proteins in human HCC specimens and matched nontumor tissue from the same patient (n ¼ 44). Statistical analysis of the data was performed using Fisher's Exact test. (b) Representative images of immunohistochemical analysis for HBx, MTA1, NF-kB-p65 and NF-kB-phospho-p65 in HCC and non-HCC samples in microtissue array. Circular marks denoted positive staining regions. (c) A multiple linear mixed model for the MTA1 intensity (arbitrary unit, AU) with those of HBx or NF-kB-p65 and the interaction between these markers and disease group fitted as covariates was assembled. Positive association between MTA1 and HBx and MTA1 and NF-kB-p65 intensity was observed in the HCC patients but not in non-HCC patients. Particularly, in HBx-positive HCC patients, there was a significant positive association between NF-kB-p65 and MTA1 intensity (Po 0.0001).
conceivable that MTA1 may affect the net transcription of the components of NF-kB pathway, and consequently, affect the signaling.
Both inflammation and MTA1 have been linked to cancer, particularly to HCC. Chronic inflammation in liver, depending on the magnitude of NF-kB activity, promotes hepatocarcinogenesis whereas MTA1 overexpression is known to associate with tumor growth and metastasis (Toh et al., 1995; Hamatsu et al., 2003; Bagheri-Yarmand et al., 2004; Giannini and Cavallini, 2005; Maeda et al., 2005; Jang et al., 2006; Kidd et al., 2006; Manavathi and Kumar, 2007; Manavathi et al., 2007b) . Nevertheless, the role of the nucleosome remodeling histone deacetylase complex in NF-kB signaling remains unknown until our recent discovery. Our recent study showed that MTA1, the founding member of the nucleosome remodeling histone deacetylase family of coregulators, is a part of NF-kB pathway and regulates host inflammatory response. Here we took this observation further and established regulatory contribution of MTA1/NF-kB cross talk in the transactivation activity of HBx. Results from ChIP studies suggested that HBx may use p65 as a coactivator and that HBx/p65 recruitment to the MTA1 promoter is correlated with the recruitment of H4-specific acetyltransferase complexes. The overexpression of p65 can also mimic the effect of HBx-mediated stimulation of the MTA1 transcription. However NF-kB, which is known to regulate the transcription of many acutephase proteins (Pahl, 1999) , requires other transcription factor and coregulator such as SRC-3 (Anderson and Kedersha, 2007) for its maximum activity. In this context, it is worth mentioning that the removal of MTA1 had a profound impairment of HBx transactivation and expression of the NF-kB's targets, for example COX2 and TNF-a. These findings suggest an integral role of MTA1 in the previously shown regulation of NF-kB activity by HBx and support the notion that MTA1 is required efficient transactivation of HBx in hepatocytes. Although HBx has been shown to influence a large number of molecules in the cell lines, only a few have been shown to be involved in the physiologically relevant human specimens as well. In this context, this study has used both the model systems and points to the fact that the newly described HBx/MTA1/NF-kB pathway may be physiologically relevant in the pathogenesis of HCC. Because TNF-a is a target as well as activator of NF-kB, the status of MTA1 in HBx-expressing cells is likely to have an important effect on carcinogenesis process. These findings suggest that MTA1 may not only represent a novel HCC prognostic indicator (Hamatsu et al., 2003) , but also can be a therapeutic target.
Materials and methods
Materials
Antibodies against IkBa (sc-371), NF-kB p65 (sc-372), phospho-NF-kB p65 (sc-33020) and NF-kB p65 (286-H) X (sc-7151 X) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). COX2 antibody (4842) (Lee et al., 1995) . Plasmids pSI-HBx and pSI-GFP plasmids were cloned as described (Keasler et al., 2007) . pCMVXF and pCMV-Core are kind gifts from Dr A Siddiqui, University of Colorado Health Sciences, Denver, CO. pSG5-HBx full-length and pSG5-HBx mutant constructs are from Dr V Kumar, International Centre for Genetic Engineering and Biotechnology, India. Cells used were obtained from the American Type Culture Collection. HepG2-X is a gift from Dr Mien-Chie Hung, MD Anderson Cancer Center, Houston, TX. All cell types were cultured as described previously or otherwise stated (Bergametti et al., 1999; Manavathi et al., 2007a) .
Cells and tissue
HepG2 liver cells, HEK 293 cells and NIH3T3 cells were obtained from the American Type Culture Collection. HepG2X is a gift from Dr Mien-Chie Hung, Molecular and Cellular Oncology, MD Anderson Cancer Center. All cell types were cultured as described previously or otherwise stated (Bergametti et al., 1999; Manavathi et al., 2007a) . Human HCC and nontumor tissues were obtained from the Qidong Liver Cancer Institute in Shanhair, People's Republic of China, as described in Slagle et al. 1991 . There was evidence of HBV infection (circulating antibody to HBV surface antigen, antibody to HBV core antigen or HBV DNA integrated into tumor DNA) for all patients. Samples were collected according to institutional IRB approvals. Tissue microarray sections (LVC961) were obtained from Pantomics Inc. (Richmond, CA, USA).
Quantiative RT-PCR Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and first-strand cDNA synthesis was carried out with SuperScript II reverse transcriptase (Invitrogen) using 2 mg of total RNA and poly (dT) primer.
ChIP and reporter assays HepG2 cells were transiently transfected with HBx expression vector before ChIP analysis and reporter assays. ChIP assays were carried out by using Flag antibody, NF-kB, MTA1 and H4 acetylation antibodies as described previously (Gururaj et al., 2006; Manavathi et al., 2007a) . The primers used for ChIP are listed in Supplementary Tables 1. MTA1-luciferase and NF-kB-luciferase assay were performed according to the manufacturer's instructions (Promega, Madison, WI, USA).
siRNA transfection siRNA against MTA1 and negative control siRNA were purchased from Dharmacon (Chicago, IL, USA). Cells were seeded at 40% density 24 h before transfection in six-well plates. Transfection was performed using Oligofectamine (Invitrogen) according to the manufacturer's instructions. Cells were subsequently subjected to further studies after 36 h of transfection. Western blot analyses were performed as described previously (Manavathi et al., 2007a) .
EMSA Nuclear extracts were prepared using a Nonidet P-40 lysis method (Schreiber et al., 1989) . EMSA for DNA binding was performed using the annealed and [g-32 P] ATP end-labeled NF-kB Consensus Oligonucleotide (Promega) or MTA1 in a 20 ml reaction mixture for 15 min at 20 1C. The reactions were then terminated and run on a nondenaturing 5% polyacrylamide gel and imaged by autoradiography. Supershift complex was detected by the addition of 1 mg of antibodies.
Immunohistochemical analysis
The immunoperoxidase staining method used in these studies was a modification of the avidin-biotin complex technique as described previously. The modifications from the standard method were incorporated to ensure high sensitivity and specificity. Tissue microarray sections (LVC961; Pantomics Inc.) were deparaffinized, dehydrated and subjected to antigen retrieval using PT Module (Thermo Fisher Scientific, Fremont, CA, USA) for 30 min at room temperature. The endogenous peroxidase activity was blocked by incubation in 0.3% hydrogen peroxide for 10 min and the slides were then treated with 10% normal horse or goat serum for 30 min. Incubation with primary antibodies was performed at 4 1C overnight. Following washes with phosphate-buffered saline, the slides were incubated with biotinylated secondary antibodies and incubated with avidin-horseradish peroxidase complex (Vector Laboratories, Burlingame, CA, USA). Detection was performed with the 0.125% aminoethylcarbazole chromogen substrate solution (Sigma Chemical Co.). In the study for the correlation of NF-kB expression, a polyclonal antibody (Abcam) was used to detect NF-kB in 25 hepatitis cancer (HCC) tumor specimens and 14 non-HCC cases. Concentrations of the antibodies used were as follows: NF-kB, 0.200 mg/ml (diluted 1:800), a polyclonal antibody of p-NF-kB p65 (Ser 536, SC-33020) from Santa Cruz Biotechnology, 0.2 mg/ml (diluted 1:100), a polyclonal antibody of MTA1 (IHC-00026) (diluted 1:200, from Bethyl Laboratories Inc.) and monoclonal antibody of HBx, 1 mg/ml (diluted 1:50; Chemicon).
Imaging analysis
To ensure absolute objectivity of the immunohistochemical studies, we used in these experiments the ACIS III Automated Cellular Imaging System (DAKO) to analyze tissues scoring and quantification (nuclear or membrane and cytoplasm applications based on percent and intensity). The percentage of positive tumor cells was used for statistical analysis.
Statistical analysis and reproducibility
The results are given as the mean±standard error. Statistical analysis of the data was performed by using Student's t-test, Fisher's Exact test or otherwise described.
